These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients. Rodrat S; Yamanont P; Tankanitlert J; Chantraraksri U; Fucharoen S; Morales NP Pharmacology; 2012; 90(1-2):88-94. PubMed ID: 22759897 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of deferiprone in patients with β-thalassaemia: impact of splenectomy and iron status. Limenta LM; Jirasomprasert T; Jittangprasert P; Wilairat P; Yamanont P; Chantharaksri U; Fucharoen S; Morales NP Clin Pharmacokinet; 2011 Jan; 50(1):41-50. PubMed ID: 21028920 [TBL] [Abstract][Full Text] [Related]
4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Daar S; Pathare AV Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126 [TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Taher A; Sheikh-Taha M; Sharara A; Inati A; Koussa S; Ellis G; Dhillon AP; Hoffbrand AV Acta Haematol; 2005; 114(3):146-9. PubMed ID: 16227677 [TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174 [TBL] [Abstract][Full Text] [Related]
7. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174 [TBL] [Abstract][Full Text] [Related]
10. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304 [TBL] [Abstract][Full Text] [Related]
11. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of combined desferrioxamine and deferiprone versus single desferrioxamine therapy in patients with major thalassemia. Zareifar S; Jabbari A; Cohan N; Haghpanah S Arch Iran Med; 2009 Sep; 12(5):488-91. PubMed ID: 19722772 [TBL] [Abstract][Full Text] [Related]
13. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716 [TBL] [Abstract][Full Text] [Related]
14. High doses of deferiprone may be associated with cerebellar syndrome. Beau-Salinas F; Guitteny MA; Donadieu J; Jonville-Bera AP; Autret-Leca E BMJ; 2009 Jan; 338():a2319. PubMed ID: 19164394 [No Abstract] [Full Text] [Related]
15. Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients. Morales NP; Rodrat S; Piromkraipak P; Yamanont P; Paiboonsukwong K; Fucharoen S Biomed Pharmacother; 2022 Jan; 145():112381. PubMed ID: 34736078 [TBL] [Abstract][Full Text] [Related]